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Available online 31 March 2016Adults with congenital heart disease represent a rapidly growing patient group. Dysfunction of the right ventricle is
often present, and right heart failure constitutes themain cause of death. Heart failure therapies used in acquired left
heart failure are often initiated in adults with right heart failure due to congenital heart disease, but the right ventri-
cle differs substantially from the left ventricle, and the clinical evidence for this treatment strategy is lacking.
In this review, we identiﬁed existing clinical studies evaluating the effects of ACE inhibitors, angiotensin II recep-
tor blockers and aldosterone antagonists in adults with congenital heart disease by a systematic literature search.
From 13 identiﬁed studies no clear evidence of beneﬁcial effects was found, but the design of the studies limits
the validity of the results. The studies in general include low numbers of patients, have short follow-up periods
and evaluate surrogate endpoints instead of hard clinical endpoints. Speciﬁc evaluation of symptomatic patients
with a systemic right ventricle indicates that these patientsmay beneﬁt fromRAAS inhibitory treatments, but this
requires further investigation.
To conclude, existing studies do not support the use of RAAS inhibitory treatments in right heart failure due to con-
genital heart disease but contain important limitations. Hence, there is a need for newwell-designed trials including
higher numbers of patients and validated endpoints to optimize and guide future treatment of this patient group.
© 2016 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Right heart failure is a frequent complication in adults with congenital
heart disease (CHD) and constitutes the main cause of death in this pa-
tient group [1]. Right heart failure has been studied sparsely compared
to left heart failure, and as a consequence, no treatment exists that effec-
tively targets the failing right ventricle (RV). Left heart failure knowledge
and treatment guidelines are often extrapolated to conditions with a fail-
ing right heart, but this generalization implies major issues and contrasts
current recommendations. Hence, there is a fundamental need for
thorough evaluation of current knowledge and treatment practice. This
review evaluates the existing studies investigating the role of the renin–
angiotensin–aldosterone-system (RAAS) in right heart failure due to
CHD and the effects of RAAS inhibitory treatments.
1.1. The right ventricle versus the left ventricle
The RV differs substantially from the left ventricle (LV). They com-
pose different anatomical structures, with the right ventricle being aarhus University Hospital, Palle
en-Kudsk).
eliability and freedom from bias
land Ltd. This is an open access articlcrescent shaped, thin-walled compliant chamber contracting in the lon-
gitudinal direction, as opposed to the ellipsoid, thick-walled left ventri-
cle, which primarily contracts with a radial motion [2]. Consequently
the RV is more sensitive to changes in afterload than the LV [3]. The
RV and the LV derive from different embryological cell lineages [4]
and express distinctive gene patterns [5]. When subjected to pressure
overload, the expression of genes essential to adaptive remodeling
correlates with the degree of hypertrophy in the LV. In the RV, on the
other hand, maladaptive factors related to apoptotic pathways are acti-
vated, and genes necessary for the contractile performance of the
cardiomyocytes are relatively down regulated [6]. Adrenergic α1-
receptor stimulation increases contractility in the LV, but in the RV
contractility is impaired [7]. The ventriclesmay also respond very differ-
ently to the same therapeutic agent. Epoprostenol is life saving in
pulmonary arterial hypertension and associated RV dysfunction but
increases mortality in acquired left heart failure [8].1.2. Right heart failure in congenital heart disease
Of all major congenital abnormalities, CHD accounts for approxi-
mately one-third [9], and the incidence of moderate to severe CHD is
approximately 6 in 1000 live births, the majority with the need for
structural and/or medical interventions. A few years ago many of
these children died at an early age due to acute or chronic heart failure,e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sive care, more patients with CHD survive into adulthood, forming a
new and growing population of adults with CHD. Consequently, adults
with CHD now outnumber children with CHD [10].
Adults with CHD predominantly develop failure of the RV, which
may be inducedbypressure overloador volumeoverload (Table 1). Sur-
gical procedures e.g. atrial switch repair of transposition of the great ar-
teries, after which the RV becomes the systemic ventricle, may also
contribute to thepathology. In general the RV tolerates volumeoverload
better than pressure overload [11], but all the defects listed in Table 1
may lead to deterioration of RV function and the development of symp-
tomatic right heart failurewith exercise intolerance, fatigue, ﬂuid reten-
tion and dyspnea.
Right heart failure in adults with CHD is often associated with ar-
rhythmias, pulmonary hypertension and the presence of remaining an-
atomical abnormalities including stenoses, valve regurgitations and
residual shunts. Arteriosclerosis and subsequent myocardial ischemia
is much less frequent in adults with CHD than adults with acquired
left heart failure, but still a higher prevalence of traditional cardiovascu-
lar risk factors including hypertension, obesity and dyslipidemia has
been observed in adults with CHD compared to the general population
[12]. Together these factors add to the complexity of the management
of this patient group and should be kept in mind when applying treat-
ment strategies.1.3. The renin–angiotensin–aldosterone-system and heart failure
Renin is released from the juxtaglomerular cells of the kidneys in
response to low pressures. It is converted to angiotensin I by
Angiotensinogen produced by the liver, which is then converted to an-
giotensin II by angiotensin converting enzyme (ACE) in the lungs. The
hemodynamic effects of angiotensin II include stimulation of aldoste-
rone production and systemic vasoconstriction and, consequently,
ﬂuid retention and increased systemic blood pressures. But it also has
a number of direct cardiac effects. Angiotensin II induces hypertrophy
and apoptosis of the cardiomyocytes, and it is the most important regu-
lator of the development of myocardial ﬁbrosis. These effects are main
components of cardiac remodeling, which is a maladaptive response
causing ventricular dilatation and cardiac dysfunction [13]. Aldosterone
inﬂuences blood pressure regulation by increasing reabsorption of
water and sodium in the kidneys, but it also promotes cardiac ﬁbrosis
and endothelial dysfunction. The improved survival in patients with
left heart failure treated with the aldosterone antagonists is believed
to be due to diuretic effects, reduced ﬁbrosis and improved endothelial
function [14,15].Table 1
Etiology and mechanisms of right ventricular overload in congenital heart disease.
Pressure overload Right ventricular outﬂow obstruction
• Right ventricular outﬂow tract obstruction
• Pulmonary valve stenosis
• Pulmonary atresia
• Pulmonary arterial stenosis
Systemic right ventricle
• Congenitally corrected transposition of the great arteries
• After atrial switch repair of transposition of the great arteries
• Right ventricle in a univentricular circulation
Pulmonary arterial hypertension
Volume overload Left-to-right shunt
• Atrial septal defect □
• Atrioventricular septal defect
• Total or partial anomalous pulmonary venous return
Pulmonary regurgitation
• After Fallot repair
Tricuspid valve regurgitation
• Ebstein´s anomaly
• Due to right ventricular dilatationLarge randomized controlled trials have demonstrated solid beneﬁ-
cial effects of RAAS inhibition in acquired left heart failure with an aver-
age reduction in 1-year mortality of 16% after treatment with ACE
inhibitors [16]. Prevention of the deleterious effects induced by in-
creased activation of the RAAS is now a keystone in the treatment of ac-
quired left heart failure, but the role of the RAAS and the therapeutic
potential of RAAS inhibition in right heart failure caused by CHD remain
unclear.
1.4. The right ventricle and the renin–angiotensin–aldosterone-system
Studies indicate that the RAAS exerts effects on the RV alongwith its
effects on the LV. In experimental studies, failure of the RV is associated
with increased activation of the RAAS [17], but when investigating the
effects of RAAS inhibition results are contradictory [18–20]. In humans,
the density of angiotensin II receptors is the same in the RV as in the LV
of the healthy heart [21], and in failing hearts the angiotensin II receptor
subtype 1 is selectively down regulated both in the failing RV and the
failing LV [22]. In patients with mild hypertension RAAS inhibition im-
proved RV myocardial performance index (an echocardiographic mea-
sure of combined systolic and diastolic function) unrelated to the
reduction in blood pressure [23], and in a large cross sectional study
the use of RAAS inhibitors was associated with changes in RVmorphol-
ogy independent of LV effects [24]. In adults with CHD, the activity of
neurohormonal systems including the RAAS is increased. Bolger et al.
studied 53 patients with CHD comprising 4 anatomical groups (single
ventricle physiology, tetralogy of Fallot, systemic right ventricle and
others (including septal defects and patent ductus arteriosus)) and
compared them to healthy controls. Neurohormonal activation oc-
curred in a similar way across different anatomical groups suggesting
themolecularmechanisms involved in the development of heart failure
in CHD to be independent of the anatomical defect. Furthermore, the
neurohormonal activation was very alike the activation seen in adults
with acquired left heart failure suggesting that adults with CHD may
beneﬁt from neurohormonal blocking treatments like patients with ac-
quired left heart failure [25]. A more recent study compared 104 adults
with CHD and RV dysfunction (primarily tetralogy of Fallot and pulmo-
nary atresia) to healthy controls. They found no differences in angioten-
sin II and aldosterone levels between the CHD group and the controls
[26]. This incongruencewith previous ﬁndingsmay be explained by dif-
ferent compositions of the study populations.While Bolger et al. includ-
ed patients with both left and right cardiac lesions; Lemmer et al.
primarily investigated patients with lesions compromising the RV.
Thus, the role of RAAS activation in right heart failure associated
with CHD remains unclear, speciﬁc studies are needed to evaluate the
effects of RAAS inhibition in patients with CHD.
2. What do we know?
Using Pubmed, we performed a systematic literature search to iden-
tify studies investigating the effects of ACE inhibitors or angiotensin II
receptor blockers in adults and older children (age N 13) with CHD
and right heart failure conducted between 1995 and 2015. Additionally,
all relevant reference lists were screened manually. Studies investigat-
ing adults with types of CHD that involves an increased load on the RV
and thereby potentially the development of RV dysfunction and failure
were included. The RV overloading condition could be due to the origi-
nal defect or post-surgical. Case reports have been excluded from this
review.
2.1. Existing clinical studies of RAAS inhibition in adult congenital heart
disease
From the literature search, 13 studies investigating the effects of
RAAS inhibition in patients with CHD were identiﬁed (Tables 2 and 3).
Patients with a univentricular heart and a passive blood ﬂow to support
Table 2
Clinical studies investigating the effects of ACE inhibitory and angiotensin II blocking treatments in adult congenital heart disease.
Reference Design Treatment Duration Population N Findings
Hopkins, 1996
[29]
Prospective cohort study Enalapril
(2.5 mg/day)
Captopril
(6.25 mg × 3/day)
399 ± 313 days Cyanotic CHD patients with:
– Anatomical obstruction
of RVOT
– Eisenmenger syndrome
Mean age: 32 ± 9 years
NYHA class: II–III
10 Treatment with enalapril/captopril caused:
– Improvement in NYHA class
– A trend towards an increase in oxygen
SAT and a decrease in systolic BP
Treatment was discontinued in 3 patients
Kouatli, 1997
[27]
Randomized, double
blind, placebo-controlled,
crossover trial
Enalapril
(0.2–0.3 mg/kg/day)
10 weeks Fontan patients (4–19 years
after surgery)
Mean age: 14.5 ± 6.2 years
NYHA class: I
18 Compared to placebo treatment with
enalapril caused:
– A decrease in the mean percent increase
in cardiac index from rest to max
exercise
– No difference in HR, BP, cardiac index or
diastolic ﬁlling patterns at rest
– No difference in exercise variables
Hechter, 2001
[32]
Retrospective
observational cohort
study
Various ACE inhibitors
and dosages
Minimum 6
months
Patients with systemic RV after
atrial switch repair of TGA
Mean age: 31 years (range
26–42 years)
NYHA class: N/A
14 Treatment with ACE inhibitor caused:
– No changes in resting variables (HR,
systolic BP, LVEF and RVEF)
– No changes in max exercise variables
(max HR, max systolic BP, max oxygen
uptake, max LVEF and max RVEF)
Some patients improved max oxygen uptake
and exercise duration
Lester, 2001 [31] Randomized
placebo-controlled
crossover study
Losartan
(25–50 mg/day)
8 weeks Patients with systemic RV after
atrial switch repair of TGA
Age: N13 years
NYHA class: N/A
7 Compared to placebo treatment with
losartan caused:
– Improvement in exercise duration and
increased RVEF
– Reduced systemic AV-valve regurgitant
volume and area
– Decreased systolic BP
No adverse effects of the treatment were found
Ohuchi, 2001
[28]
Prospective cohort study
(Subgroup analysis of case
control study)
Enalapril
(0.1 mg/kg/day)
6.8 months Fontan patients
Mean age: 14 ± 3 years
NYHA class: N/A
18 Treatment with enalapril caused:
– No change in EF of the systemic ventri-
cle (the same as non-treated controls)
– No changes in cardiac autonomic ner-
vous activity (incl. HR variability and
baroreﬂex sensitivity)
Robinson, 2002
[33]
Prospective cohort study Enalapril
(0.5 mg/kg/day)
12 months Patients with systemic RV
after atrial switch repair of
TGA
Mean age: 13.8 ± 3 years
NYHA class: I
8 Treatment with enalapril caused:
– Increased body mass index and de-
creased max oxygen uptake
– No change in other exercise variables
– Increase in resting respiratory rate
– Decreased BP
Dore, 2005 [34] Randomized
double-blind,
placebo-controlled,
crossover, clinical trial
Losartan
(50–100 mg/day)
106 ± 6 days Patients with systemic RV
because of:
– Atrial switch repair of
TGA
– Congenitally corrected
TGA
Mean age: 30.3 ± 10.9 years
NYHA class: I–II
29 Compared to placebo losartan treatment
caused:
– No effect on max oxygen uptake or ex-
ercise duration
– No effect on systolic BP or HR at rest or
during exercise
– No effect on RVEF or NT-pro-BNP levels
– A trend towards increased levels of
AngII
Therrien, 2008
[35]
Randomized, double
blind, placebo-controlled
clinical trial
Ramipril
(10 mg/day)
12 months Patients with systemic RV
after atrial switch repair of
TGA
Mean age: 26 ± 2 years
NYHA class: I–II
17 Compared to placebo ramipril treatment
caused:
– No effect on exercise capacity or quality
of life
– No improvement in RVEF or RV volumes
Van der Bom,
2012 [36]
Randomized, double
blind, placebo-controlled
clinical trial
Valsartan
(160 mg × 2 /day)
3.2 years Patients with systemic RV
because of:
– Atrial switch repair of TGA
– Congenitally corrected
TGA
88 Compared to placebo valsartan treatment
caused:
– Steady RV EDV and mass (increase in
the placebo group)
– No effect on RVEF, exercise capacity or
(continued on next page)
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Table 2 (continued)
Reference Design Treatment Duration Population N Findings
Mean age: 33 ± 10 years
NYHA class: I–IV
quality of life
– A trend towards decreased systemic BP
In the subgroup of symptomatic patients
there was no reduction in RVEF in valsartan
group but signiﬁcant reduction in the
placebo group
The same incidence of adverse effects and
clinical events in the valsartan and the
placebo group was reported
Babu-Narayan,
2012 [30]
Randomized,
double-blind,
placebo-controlled
clinical trial
Ramipril
(10 mg/day)
26.3 ± 2.6 weeks Patients with repaired ToF
with moderate/severe
pulmonary regurgitation and
RV dilatation
Mean age: 30.1 ± 10.3 years
NYHA class: I–II
64 Compared to placebo ramipril treatment
caused:
– Improved RV and LV long axis shorten-
ing
– No change in RVEF, RV mass or RV vol-
umes
– No change in neurohormone levels,
NYHA class, or exercise capacity
In the subgroup with restrictive RV, ramipril
improved LV systolic function
No adverse effects were reported
Tutarel,
2012 [37]
Retrospective
observational case control
study
Enalapril
(10 mg × 2/day)
13.3 ± 4 months Patients with systemic RV after
atrial switch repair of TGA
Mean age: 25.2 ± 3.5 years
NYHA class: II
14 Enalapril treatment caused:
– Decrease in NT-pro-BNP levels (increase
in control group)
– No change in max oxygen uptake, NYHA
class or RV function
No adverse effects on heart failure
symptoms or renal function were reported
CHD: congenital heart disease; RVOT: right ventricular outﬂow tract; SAT: oxygen saturation;HR: heart rate; BP: bloodpressure; NYHA:NewYorkHeart Association; TGA: transposition of
the great arteries; RV: right ventricle; LVEF: left ventricular ejection fraction; RVEF: right ventricular ejection fraction; AngII: angiotensin II; EDV: end diastolic volume; ToF: tetralogy of
Fallot; LV: left ventricle; ESV: end systolic volume.
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improvement of RV function after treatment with ACE inhibitors [27,
28]. An adverse reduction in the mean percent increase in cardiac
index from rest to max exercise with enalapril treatment was observed
[27].
In cyanotic CHD patients, ACE inhibition improved NYHA class in 8
out of 10 patients, but treatment was discontinued in 3 patients due
to increased fatigue symptoms, although no decrease in arterial oxygen
saturation was detected in any of the patients [29]. Compared to place-
bo, treatmentwith ramipril did not improveNYHA class in patientswith
repaired tetralogy of Fallot and subsequent pulmonary regurgitation
and RV dilatation. An improvement in RV and LV long axis shortening
was observed, but the treatment did not improve other measures of
RV function or morphology [30].
A number of studies have investigated the effects of RAAS inhibition
in patients with a systemic RV after atrial switch repair of transposition
of the great arteries (Mustard or Senning operation). Although a small
crossover study (n = 7) reported improved exercise duration and RV
ejection fraction with losartan treatment [31], most studies have
found no beneﬁcial effect of RAAS inhibition in patients with systemic
RV on neither RV function nor exercise capacity [32–35]. One study
even observed a decrease in maximal oxygen uptake with enalapril
treatment [33]. A larger randomized controlled trial (n = 88) compar-
ing valsartan to placebo found that while RV end diastolic volume and
mass increased in the placebo group, there were no adverse changes
in the treatment group [36]. In the subgroup of symptomatic patients,
RV ejection fraction decreased in the placebo group but remained stable
in the valsartan group. In a recent retrospective study evaluating only
symptomatic patients (NYHA class II) with systemic RV, a decrease in
plasma levels of NT-pro-BNP with enalapril treatment compared to an
increase in the non-treated control group was observed [37]. Hard clin-
ical endpoints were only evaluated by one study [36]. In patients with
systemic RV, the overall risk of clinical events (composite endpoint of
hospitalization due to heart failure, arrhythmias, reoperation or death)
was the same for the treatment group and the placebo group. Treatmentwith aldosterone antagonists has only been investigated in very few
studies (Table 3). Short-term treatmentwith spironolactone did not im-
prove endothelial function in Fontan patients [38]. In patients with sys-
temic right ventricular morphology, 12 months treatment with
eplerenone did not change RV mass or function, nor did it affect heart
failure or collagen turnover biomarker levels [39].
3. Discussion
Until now studies investigating the effects of RAAS inhibition in
adults and older children with CHD have found no overall convincing
beneﬁcial effects in this patient group (Table 2). ACE inhibitors, angio-
tensin II receptor blockers and aldosterone antagonists seem to be
well tolerated as the studies in general report no adverse effects of the
treatments.
3.1. Limitations of clinical studies
The clinical studies performed so far may carry important limita-
tions. Firstly, they include very few patients (between 7 and 88). This
may have led to insufﬁcient power to detect effects (beneﬁcial or ad-
verse) of the treatments. Despite being a growing patient group, the
number of adults with CHD is still very low compared to the number
of patients with acquired left heart failure. Conducting larger trials in
adultswith CHD is therefore challenging and requires broadmulticenter
collaborations. Additionally, adults with CHD are young and otherwise
healthy people, who normally experience very few symptoms. This
may decrease their motivation for participating in clinical studies fur-
ther complicating the inclusion process [36].
Secondly, the treatment duration of the studies is often relatively
short e.g. 12 months or less [27,28,30,31,38,39]. The main beneﬁt of
RAAS inhibition is expected to be a result of long-term neurohormonal
blockade and not short-term hemodynamic effects, and consequently
beneﬁcial effects may not be detectable if the follow-up period is too
short. However, in severe left heart failure, enalapril improved NYHA
Table 3
Clinical studies investigating the effects of aldosterone receptor blockers in adult congenital heart disease.
Reference Design Treatment Duration Population N Findings
Mahle,
2009 [38]
Prospective cohort study Spironolactone
(50 mg/day)
4 weeks Fontan patients
Mean age: 28 years
NYHA class: I–II
10 Treatment with spironolactone caused:
– No effects on endothelial function
measured by ﬂow mediated dilation
– No effects on serum cytokine levels
Dos,
2013 [39]
Randomized, double blind,
placebo-controlled trial
Eplerenone
(50 mg/day)
12 months Patients with systemic RV after
atrial switch repair of TGA
Mean age: 26.4 years
NYHA class: I–II
25 Compared to placebo treatment with
eplerenone caused:
– No effects on RV mass or RVEF
– No effects on neurohormonal or
collagen turnover biomarker levels
NYHA: New York Heart Association; TGA: transposition of the great arteries; RV: right ventricle; TGA: transposition of the great arteries; RVEF: right ventricular ejection fraction.
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asymptomatic patients with reduced ejection fraction (LVEF b 35%) the
incidence of development of heart failure was lower in the enalapril
group compared to the placebo group after three months of treatment
[41].
Thirdly, as a consequence of the low number of included patients
and short follow-up periods, the randomized trials often evaluate surro-
gate endpoints (RV function, reported symptoms or level of NT-pro-
BNP) instead of hard clinical endpoints (hospitalization or mortality)
[27,30,31,34,35]. Evaluation of RV function in adults with CHD implies
a number of challenges. In adults with acquired left heart failure clear
deﬁnitions of normal vs. abnormal function assessed by different imag-
ingmodalities are available, but in adults with CHD and right heart fail-
ure this is not the case. The complex shape of the RVmakes it difﬁcult to
evaluate, and deﬁning normal values of RV function, e.g. when the RV
performs as the systemic ventricle, is complicated [42].
Furthermore, adults with CHD in general do not recognize or report
symptoms of for example exercise intolerance, and often there is a high
discrepancy between the patients' own assessments of their functional
capacity and objective measures of RV function and exercise variables
[26,27,33,34]. This limits the use of self-reported symptoms in clinical
studies with this patient group.
Enrolling a sufﬁcient number of patients to evaluate clinical end-
points in studies of adultswith CHDmay, however, be very difﬁcult con-
sidering the low number and the heterogeneity of the patient group.
Consequently, prior identiﬁcation and validation of suitable surrogate
endpoints is essential for evaluation of safety and efﬁcacy of heart
failure therapies in adults with CHD in future studies [43].
3.2. The role of the renin–angiotensin–aldosterone-system in the
development of right heart failure
The lack of demonstrated effects of RAAS inhibitory treatments in
CHD and right heart failure in clinical trials may be explained by study
limitations, but more intrinsic reasons ought to be considered too. The
metabolic inactivation of ACE-inhibitory drugs is much more effective
in the RV compared to the LV [44], and the use of ACE inhibitors did
not affect neurohormone levels in adult patients with CHD [25]. The in-
tracellular angiotensin signaling pathway is down regulated in the fail-
ing RV compared to the failing LV of children with CHD and RV or LV
outﬂow obstructions, respectively [6]. In adults with an overloaded RV
due to CHD, natriuretic peptides, endothelin-1, norepinephrine and epi-
nephrine correlate closely with each other and with the dysfunction of
the RV, while renin and aldosterone levels relate only to one another
[25]. Thus, the RAAS may be a less important pathophysiological factor
in the development of right heart failure compared to left heart failure.
Baseline levels of angiotensin II are only slightly elevated in patients
with systemic RV [34], and in a larger group of patients with CHD (sys-
temic RV, tetralogy of Fallot and single ventricle), RAAS was onlyactivated in symptomatic patients contrary to other neurohormones,
which were increased in both asymptomatic and symptomatic patients
[25]. Also, aldosterone levels are signiﬁcantly lower in asymptomatic
patients with systemic RV compared to symptomatic patients. Accord-
ingly, the RAAS does not seem to be an important factor in early asymp-
tomatic stages of CHD. On the contrary, RAAS inhibition prevents RV
hypertrophy anddeterioration of RV function [36] and causes a decrease
in NT-pro-BNP [37] in symptomatic patients.
The effects of RAAS inhibition also vary with the etiology of heart
failure. In acquired left heart failurewith preserved ejection fraction (di-
astolic heart failure), the effects of RAAS inhibition are less pronounced
compared to heart failure with reduced ejection fraction (systolic heart
failure) [45], and RAAS inhibitory therapies are in general not recom-
mended in valvular heart disease [46]. Adults with CHD more often
present with diastolic dysfunction and/or valvular defects than systolic
dysfunction, which may reduce the potential effects of RAAS inhibition
in this patient group.
Also, beneﬁcial treatment strategies of one condition of CHD with
right heart failure may not apply to other conditions. Theoretically, the
vasodilatation induced by RAAS inhibition may be beneﬁcial in
conditionswith a septal defectwhere decreased systemic vascular resis-
tance may reduce the magnitude of the shunt [47], but detrimental in
patients after the Fontan procedure where venous vasodilatation may
reduce the ability to mobilize blood from the venous reserve during
exercise [27].3.3. Current recommendations and clinical practice
With no effective right heart failure treatments available, the dilem-
ma of extrapolating recommendations from the treatment guidelines
for acquired left heart failure persists. But despite some parallels in the
remodeling processes and neurohormonal activation in heart failure re-
gardless of the etiology, the differences between acquired left heart fail-
ure and right heart failure associatedwith CHD are considerable (Fig. 1).
Recently, the American Heart Association have stated that older adults
with CHD (age N 40) should only be treated at specialized centers, as
they cannot be directly compared to patientswith acquired heart failure
[48].
Today's treatment guidelines in general include very few recom-
mendations for medical treatment of heart failure in adults with CHD.
According to the ACC/AHA 2008 Guidelines for the Management of
Adults With Congenital Heart Disease [49], the use of ACE inhibitors
are restricted to 1) patients with atrioventricular septal defects and
symptoms of chronic heart failure and 2) Fontan patients with dysfunc-
tion of the systemic ventricle. Aldosterone antagonismmay improve the
protein losing enteropathy syndrome of Fontan patients, although the
effects have only been reported by case reports. Diuretics in general
are only recommended in patients with signs of congestion.
Fig. 1.Differences between CHD related heart failure and acquired heart failure. CHD: congenital heart disease; RV: right ventricle; LV: left ventricle; RVOT: right ventricular outﬂow tract;
RAAS: renin–angiotensin–aldosterone-system; ACE: angiotensin converting enzyme.
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with CHD in general advise against the use of traditional left heart
failure therapies in CHD, treatment with ACE inhibitors, angiotensin II
receptor blockers and aldosterone antagonists is often initiated none-
theless. Data from clinical studies reveal that patients with CHD are
often empirically treated with RAAS inhibitory drugs [32,34,35,39]. Of
the 53 patients with CHD evaluated by Bolger et al., 14 were taking
ACE inhibitors, 3 were treated with angiotensin II receptor blockers,
and 6 were treated with spironolactone [25]. In a more recent study,
only 1 of 104 adult patients with CHD and RV dysfunction were treated
with an angiotensin II receptor blocker [26], indicating that treatment
practices may have changed during the past years. A retrospective eval-
uation of patients with systemic RV after atrial switch repair of TGA re-
vealed that in the majority treatment with ACE inhibitor was initiated
based solely on the belief that the therapy might be helpful. Only a
few were treated because of dyspnea or high blood pressures [32].
4. Conclusion
Adults with CHD constitute a growing patient group often present-
ing with dysfunction and eventually failure of the RV. Traditionally,
they have been excluded from the large heart failure trials, and conse-
quently no clear evidence of effective medical heart failure therapies
are available for these patients. Clinical studies investigating heart fail-
ure therapies, including RAAS inhibitory treatments, speciﬁcally in
adults with CHD have failed to demonstrate beneﬁcial effects, but may
have been underpowered. Therefore, current clinical practice regarding
these patients is primarily based on empirical extrapolations and expert
opinions. This may include initiation of treatment with ACE inhibitors,
angiotensin II receptor blockers and aldosterone antagonists despite
the lack of clinical evidence to support this strategy. Thus, there is an ur-
gent need for well-designed trials including higher numbers of patients
and validated endpoints to optimize and guide future treatment of
adults with CHD.
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